ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. founded in 2015 and is based in Winston-Salem, North Carolina.

ProKidney Corp.

Bank of America Securities analyst Jason Gerberry reiterated a Sell rating on ProKidney yesterday and set a price target of $1.00. The company’s sh...

Bank of America Securities Keeps Their Sell Rating on ProKidney (PROK)

Prokidney Corp. (($PROK)) announced an update on their ongoing clinical study. Prokidney Corp. is currently conducting a clinical study titled ‘A P...

Current Quarter	$-0.15	Next Quarter	$-0.09
Current Year	$-0.65	Next Year	$-0.67
QoQ Growth	+40.0%	YoY Growth	-3.1%
3Y EPS CAGR	+0.0%	Target Price	$5.40
Consensus	Buy	Upside	+146.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PROK	$2.19	+4.78%	1.53M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PROK	$2.19	+4.8%	1.53M
3
4
5
6

PROK

PROK

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get ProKidney Corp. Data in Excel

Get ProKidney Corp. Data in Excel